Drugs / Remetinostat
Remetinostat
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT01433731 | Nov 2011 → Sep 2013 | primary cutaneous T-cell lymphoma | TetraLogic Pharmaceuticals | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT03875859 | Dec 2019 → May 2020 | squamous cell carcinoma | Kavita Sarin | Terminated | No outcome recorded |
| Phase 2 | NCT03180528 | Jul 2018 → Jul 2020 | skin basal cell carcinoma | Kavita Sarin | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2021-11-18 | Medivir | Results Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published medivir.com ↗
All five tumours, including a range of histological subtypes, demonstrated complete clinical and pathological resolution at week 10. |
| 2021-08-12 | Medivir | Results Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research medivir.com ↗
Results of the open-label clinical trial of the topical HDAC inhibitor, remetinostat, as neoadjuvant treatment for BCC were reported. |
| 2021-05-20 | Medivir | Results Positive results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published medivir.com ↗
All five tumours, including a range of histological subtypes, demonstrated complete clinical and pathological resolution after up to 8 weeks of treatment. |
| 2019-05-13 | Medivir | Results Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting medivir.com ↗
Initial results suggest that remetinostat gel offers a potentially effective and well-tolerated, non-surgical intervention for treatment of localized BCCs. |
| 2017-10-13 | Medivir | Results Remetinostat phase II data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage MF-type CTCL medivir.com ↗
Remetinostat also caused a clinically significant reduction in the severity of pruritus (itching) in those patients with clinically significant pruritus at the start of the study, and was highly tolerable with no systemic adverse effects. |
| 2017-04-07 | Medivir | Results Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma medivir.com ↗
Based on an intent-to-treat analysis, patients in the 1% remetinostat gel BID arm had highest proportion of confirmed responses (8/20, 40%), including 1 complete response. |
All press releases naming this drug 13 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remetinostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03180528 ↗ |
| Known as | NSC-748492 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707219 ↗ |
| Known as | SHAPE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01433731 ↗ |
| Known as | SHP-141 | “SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly” NCT01433731 ↗ |
| Action | Inhibit | “A Histone Deacetylase Inhibitor” NCT01433731 ↗ |
| Modality | Small molecule | — CHEMBL3707219 ↗ |
| Route | Topical | “Administered Topically” NCT01433731 ↗ |